Neuralstem Rating Reiterated by Zacks (CUR)
Neuralstem (NYSE:CUR)‘s stock had its “outperform” rating restated by Zacks in a research report issued to clients and investors on Wednesday. They currently have a $7.00 price objective on the stock. Zacks‘s target price would indicate a potential upside of 55.56% from the stock’s previous close.
Zacks’ analyst wrote, ” Data from Neuralstem’s Phase 1b, randomized, double-blind, placebo-controlled, multiple-dose escalation study evaluating the effects of NSI-189 in patients with Major Depressive Disorder (MDD) was presented via an oral presentation and poster at two major neuropharmacology meetings earlier this month. Below we highlight the data and discuss potential valuation of the asset. Our previous analysis of NSI-566 for the treatment of ALS, SCI, and stroke yield a fair-value of $6 per share. Adding in approximately $1.00 per share for NSI-189 raises our price target to $7 per share. We continue to be optimistic on the future of Neuralstem. “
Neuralstem (NYSE:CUR) traded up 4.17% during mid-day trading on Wednesday, hitting $4.50. 2,261,181 shares of the company’s stock traded hands. Neuralstem has a 52 week low of $1.30 and a 52 week high of $4.81. The stock has a 50-day moving average of $4.03 and a 200-day moving average of $3.62. The company’s market cap is $390.4 million. Neuralstem also was the target of a large growth in short interest during the month of June. As of June 13th, there was short interest totalling 8,108,237 shares, a growth of 6.6% from the May 30th total of 7,604,836 shares. Based on an average trading volume of 889,966 shares, the days-to-cover ratio is presently 9.1 days. Approximately 9.8% of the shares of the stock are sold short.
Neuralstem (NYSE:CUR) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.07) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.06) by $0.01. The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.35 million. On average, analysts predict that Neuralstem will post $-0.25 earnings per share for the current fiscal year.
CUR has been the subject of a number of other recent research reports. Analysts at Aegis raised their price target on shares of Neuralstem from $6.00 to $7.00 in a research note on Wednesday. They now have a “buy” rating on the stock.
Neuralstem, Inc is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.